KU 2019 Post San Antonio Breast Cancer Review
A

52 y/o With HER2+/HR- De-novo Metastatic BC / 52 y/o With T2N0 HR+/HER2- Grade II IDC

By KU 2019 Post San Antonio Breast Cancer Review FEATURING Allison Kurian, Qamar Khan, Priyanka Sharma, Virginia Kaklamani, Terry Mamounas, William Gradishar
March 12, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

17:04
Novartis Oncology

Discussion on Overall Survival Data Across 3 Phase III Trials in HR+…

Feat. G. Hortobagyi

Featured Video

18:15
Novartis Oncology

CDK4/6 Inhibitor in Postmenopausal Patients With HR+/HER2- mBC: Anal…

Feat. G. Hortobagyi

Related Content

AUTOPLAY
27:39
Breast Health Global Initiative

Metastatic Breast Disease: Treatment and Palliative Care

Feat. A. Eniu
30:05
Cleveland Clinic Taussig Cancer Institute

Hormone Receptor Positive Advanced Breast Cancer Case 1: Management …

Feat. J. Abraham, R. Finn, M. Dickler
14:37
Cleveland Clinic Taussig Cancer Institute

Hormone Receptor-Postive Advanced Breast Cancer Case 2: Patient with…

Feat. J. Abraham
18:34
Cleveland Clinic Taussig Cancer Institute

Hormone Receptor-Positive Advanced Breast Cancer: Case 3: Treatment …

Feat. J. Abraham, R. Finn, M. Dickler
11:40
Cleveland Clinic Taussig Cancer Institute

Hormone Receptor-Postive Advanced Breast Cancer Case 4: Patient with…

Feat. J. Abraham, R. Finn, M. Dickler
30:13
Nico Karssemeijer

Deep Learning Systems for Reading Mammograms and Breast Tomosynthesis

19:43
Northwestern Medicine: Chicago Live

Northwestern Live: Live Case - 47 y/o Female with History of Metasta…

Feat. D. Mullady, A. Aadam
17:54
Heather McArthur

Modern Immune Therapy in ER, HR+/HER2-, HER2+ Breast Cancer

19:23
Holy Cross 9th Annual Winter Oncology Symposium

Genetic Testing in Breast and Ovarian Cancer: BRCA1/2 and PARP Inhib…

Feat. D. Guaqueta
24:03
Holy Cross 9th Annual Winter Oncology Symposium

Early Stage Breast Cancer - Comparison of Trials of Genomic Assays -…

Feat. R. L. Mahtani
13:07
Holy Cross 9th Annual Winter Oncology Symposium

Panel Discussion on Breast Cancer: Promising Drugs and Future Treatm…

Feat. E. Segota, R. L. Mahtani, J. Burgers, M. Abu-Khalaf, B. Moy
07:43
Dana-Farber Cancer Institute

Study of Abemaciclib for Patients with RB-Positive, Triple Negative …

Feat. S. Goel
24:33
Holy Cross 9th Annual Winter Oncology Symposium

Therapeutic Strategies in HER2+ Breast Cancer - Pertuzumab, Neratini…

Feat. B. Moy
12:05
Holy Cross 9th Annual Winter Oncology Symposium

Future Directions in the Targeting of HER2+ Breast Cancer: duration …

Feat. B. Moy
12:44
Holy Cross 9th Annual Winter Oncology Symposium

Emerging Targets in ER Positive Breast Cancer: CDK4/6 inhibitors, Bc…

Feat. M. Abu-Khalaf
10:12
Holy Cross 9th Annual Winter Oncology Symposium

Emerging Targets in HER-2 Negative, TNBC and HER-3 Positive Breast C…

Feat. M. Abu-Khalaf
32:33
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Adjuvant Chemotherapy for HR+/HER2- Breast Cancer - How MINDACT, TAI…

Feat. L. Carey
11:57
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

HR+/HER2- Breast Cancer - Who Needs Extended Adjuvant Endocrine Ther…

Feat. L. Carey
07:58
Sandra Swain

ASCO 2019 End-of-study Survival Analysis from the Cleopatra Study Sh…

11:07
Baltic and Eurasia Masterclass in Clinical Oncology

Advanced Breast Cancer: Endocrine Therapy as Preferred Option for HR…

Feat. O. Pagani